Edarbi: payments to doctors
Payments that named Edarbi as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $494K
- Providers
- 11,947
- Transactions
- 29,817
- Average per transaction
- $17
The per-transaction average — $17 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,947 providers the average total is $41, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Arbor Pharmaceuticals, Inc. | $364,780 | 73.8% |
| Azurity Pharmaceuticals, Inc. | $98,518 | 19.9% |
| Takeda | $25,050 | 5.1% |
| Hikma Pharmaceuticals USA | $6,000 | 1.2% |
| Takeda Pharmaceuticals U.S.A., Inc. | $103 | 0.0% |